Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin R Flaherty

Showing results (81-90 of 204) with videos related to

Pageof 21
Sort By:
American Journal of Respiratory and Critical Care Medicine|April 21, 2022
Toll-Interacting Protein and Altered Lung Microbiota in Idiopathic Pulmonary FibrosisJay H Lipinski, John R Erb-Downward, Gary B Huffnagle, et al.
Respiratory Medicine|March 5, 2019
Frailty and geriatric conditions in older patients with idiopathic pulmonary fibrosisJamie S Sheth, Meng Xia, Susan Murray, et al.
Annals of the American Thoracic Society|April 10, 2025
Quantitative CT Measures of Lung Fibrosis and Outcomes in the National Lung Screening TrialJennifer M Wang, Swaraj Bose, Susan Murray, et al.
American Journal of Respiratory and Critical Care Medicine|August 9, 2017
A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary FibrosisJoseph M Parker, Ian N Glaspole, Lisa H Lancaster, et al.
BMC Pulmonary Medicine|December 13, 2022
Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trialAnna J Podolanczuk, John S Kim, Christopher B Cooper, et al.
Chest|February 25, 2020
A Randomized, Double-Blind, Placebo-Controlled Study of Pulsed, Inhaled Nitric Oxide in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary FibrosisSteven D Nathan, Kevin R Flaherty, Marilyn K Glassberg, et al.
Respiratory Medicine|May 20, 2014
Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosisLuca Richeldi, Vincent Cottin, Kevin R Flaherty, et al.
Annals of the American Thoracic Society|August 14, 2024
Inhaled Nitric Oxide in Fibrotic Lung Disease: A Randomized, Double-Blind, Placebo-controlled TrialSteven D Nathan, Natasa Rajicic, Rosemarie Dudenhofer, et al.
The Lancet. Respiratory Medicine|April 29, 2014
Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET studyMeiLan K Han, Yueren Zhou, Susan Murray, et al.
American Journal of Respiratory and Critical Care Medicine|October 6, 2007
Variable prostaglandin E2 resistance in fibroblasts from patients with usual interstitial pneumoniaSteven K Huang, Scott H Wettlaufer, Cory M Hogaboam, et al.
Pageof 21

Showing results (81-90 of 204) with videos related to

Sort By:
Pageof 21
American Journal of Respiratory and Critical Care Medicine|April 21, 2022
Toll-Interacting Protein and Altered Lung Microbiota in Idiopathic Pulmonary FibrosisJay H Lipinski, John R Erb-Downward, Gary B Huffnagle, et al.
Respiratory Medicine|March 5, 2019
Frailty and geriatric conditions in older patients with idiopathic pulmonary fibrosisJamie S Sheth, Meng Xia, Susan Murray, et al.
Annals of the American Thoracic Society|April 10, 2025
Quantitative CT Measures of Lung Fibrosis and Outcomes in the National Lung Screening TrialJennifer M Wang, Swaraj Bose, Susan Murray, et al.
American Journal of Respiratory and Critical Care Medicine|August 9, 2017
A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary FibrosisJoseph M Parker, Ian N Glaspole, Lisa H Lancaster, et al.
BMC Pulmonary Medicine|December 13, 2022
Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trialAnna J Podolanczuk, John S Kim, Christopher B Cooper, et al.
Chest|February 25, 2020
A Randomized, Double-Blind, Placebo-Controlled Study of Pulsed, Inhaled Nitric Oxide in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary FibrosisSteven D Nathan, Kevin R Flaherty, Marilyn K Glassberg, et al.
Respiratory Medicine|May 20, 2014
Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosisLuca Richeldi, Vincent Cottin, Kevin R Flaherty, et al.
Annals of the American Thoracic Society|August 14, 2024
Inhaled Nitric Oxide in Fibrotic Lung Disease: A Randomized, Double-Blind, Placebo-controlled TrialSteven D Nathan, Natasa Rajicic, Rosemarie Dudenhofer, et al.
The Lancet. Respiratory Medicine|April 29, 2014
Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET studyMeiLan K Han, Yueren Zhou, Susan Murray, et al.
American Journal of Respiratory and Critical Care Medicine|October 6, 2007
Variable prostaglandin E2 resistance in fibroblasts from patients with usual interstitial pneumoniaSteven K Huang, Scott H Wettlaufer, Cory M Hogaboam, et al.
Pageof 21